FBInvestor
Funds / Elmind Capital, LP
Institutional Fund

Elmind Capital, LP

New York, NYCIK 20522132 filings on record

Portfolio Value
$352.22M
Q1 2026
Holdings
34
Reported positions
New Buys
2
Opened this quarter
QoQ Change
+3.9%
from $338.85M

Portfolio Value Trend

Reported 13F value by quarter

Portfolio value trend — upgrade to see history

Upgrade

Top Allocations

Largest positions by weight

  • Cogent Biosciences Inc12.8%
  • Syndax Pharmaceuticals Inc12.3%
  • Celldex Therapeutics Inc New7.8%
  • Cytomx Therapeutics Inc6.1%
  • Kalvista Pharmaceuticals Inc5.8%
  • Cg Oncology Inc5.6%
  • Other49.6%

Portfolio Holdings

34 positions · Q1 2026

#SecuritySharesValue% Port.Δ SharesActivity
1Cogent Biosciences Inc1.17M$45.06M12.8%0Held
2Syndax Pharmaceuticals Inc1.85M$43.33M12.3%0Held
3Celldex Therapeutics Inc New865.0K$27.44M7.8%0Held
4Cytomx Therapeutics Inc4.55M$21.39M6.1%+3.85MAdded
5Kalvista Pharmaceuticals Inc1.02M$20.56M5.8%+220.0KAdded
6Cg Oncology Inc291.8K$19.75M5.6%200.7KReduced
7Vera Therapeutics Inc482.5K$19.41M5.5%0Held
8Vaxcyte Inc316.5K$18.39M5.2%+25.0KAdded
9Pharvaris N V475.8K$13.44M3.8%0Held
10Tyra Biosciences Inc350.0K$13.40M3.8%0Held

24 more holdings on Premium

See this fund's complete portfolio, full position changes, and activity history.

Unlock full portfolio